trial · 2022

Clinical Trial on Agitation in Alzheimer's Dementia

IGC Pharma, LLC

Unreviewed source record: Inclusion in the index is not an endorsement of the methods, findings, or clinical relevance. This page is excluded from search indexing until editorial review.

Study designClinical trial

Evidence classcontrolled-trial

Open accessReported open

CitationsNot available

Abstract

The purpose of this study is to assess the efficacy of the oral medication IGC-AD1, a THC-based (Delta-9-Tetrahydrocannabinol) formulation administered twice a day on Agitation in patients with mild to severe dementia from Alzheimer's.

Topics and compounds

Alzheimer DiseaseAgitation,PsychomotorCare Giving BurdenNPSAggression

Continue with the source

Open original record ↗